Karl B LemstrÃ¶m

List of Publications by Year
in descending order

111 papers	2,602 citations	172457 29 h-index	206112 48 g-index
115 all docs	115 docs citations	115 times ranked	2738 citing authors

#	Article	IF	Citations
1	Chronic Allograft Rejection. Immunological Reviews, 1993, 134, 33-81.	6.0	240
2	Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts. Circulation, 2010, 121, 1413-1422.	1.6	131
3	Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation, 2010, 122, 1725-1733.	1.6	129
4	Vascular Endothelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis. Circulation, 2002, 105, 2524-2530.	1.6	119
5	Usefulness of extracorporeal membrane oxygenation as a bridge to lung transplantation: A descriptive study. Journal of Heart and Lung Transplantation, 2011, 30, 103-107.	0.6	115
6	Angiopoietin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis. Circulation, 2003, 107, 1308-1314.	1.6	99
7	De novo expression of endothelial sialyl Lewis(a) and sialyl Lewis(x) during cardiac transplant rejection: superior capacity of a tetravalent sialyl Lewis(x) oligosaccharide in inhibiting L-selectin-dependent lymphocyte adhesion.. Journal of Experimental Medicine, 1995, 182, 1133-1141.	8.5	95
8	Cytomegalovirus Antigen Expression, Endothelial Cell Proliferation, and Intimal Thickening in Rat Cardiac Allografts After Cytomegalovirus Infection. Circulation, 1995, 92, 2594-2604.	1.6	85
9	Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney International, 1996, 50, 526-537.	5.2	72
10	Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury and Chronic Rejection Through Microvascular Protection. Circulation, 2011, 124, 1138-1150.	1.6	69
11	Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovascular Drugs and Therapy, 1999, 13, 159-168.	2.6	67
12	Prevention of Cardiac Allograft Arteriosclerosis by Protein Tyrosine Kinase Inhibitor Selective for Platelet-Derived Growth Factor Receptor. Circulation, 1999, 99, 2295-2301.	1.6	63
13	Cytomegalovirus Infectionâ€“Enhanced Cardiac Allograft Vasculopathy Is Abolished by DHPG Prophylaxis in the Rat. Circulation, 1997, 95, 2614-2616.	1.6	56
14	Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. American Journal of Pathology, 2012, 181, 1607-1620.	3.8	45
15	Differential regulation of somatostatin receptor types 1â€“5 in rat aorta after angioplasty. FASEB Journal, 1999, 13, 387-394.	0.5	43
16	PDGF-A, -C, and -D but not PDGF-B Increase TGF-Î²1 and Chronic Rejection in Rat Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 691-698.	2.4	43
17	Blockade of CD28/B7-2 Costimulation Inhibits Experimental Obliterative Bronchiolitis in Rat Tracheal Allografts. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 724-729.	5.6	42
18	Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function. American Journal of Transplantation, 2013, 13, 2019-2034.	4.7	41

#	Article	IF	Citations
19	Towards understanding the pathophysiology of chronic rejection. The Clinical Investigator, 1992, 70, 780-90.	0.6	40
20	Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1421-1429.	5.6	40
21	Three decades of heart transplantation in Scandinavia: longâ€term followâ€up. European Journal of Heart Failure, 2013, 15, 308-315.	7.1	38
22	Common Protective and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allograft Vasculopathy. Circulation Research, 2006, 98, 1373-1380.	4.5	37
23	Ischemiaâ€“Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. American Journal of Transplantation, 2016, 16, 1160-1172.	4.7	37
24	Natural course and risk factors for impaired renal function during the first year after heart transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 633-640.	0.6	35
25	Combined Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Inhibition in Rat Cardiac Allografts: Beneficial Effects on Inflammation and Smooth Muscle Cell Proliferation. Transplantation, 2005, 79, 182-189.	1.0	34
26	Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC. Transplant International, 1994, 7, 365-370.	1.6	33
27	Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart-lung allograft recipients. Clinical Transplantation, 2001, 15, 77-88.	1.6	33
28	Angiopoietin-2 Inhibition Prevents Transplant Ischemia-Reperfusion Injury and Chronic Rejection in Rat Cardiac Allografts. American Journal of Transplantation, 2014, 14, 1096-1108.	4.7	32
29	Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1145-1152.	5.6	29
30	Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. Journal of Heart and Lung Transplantation, 2010, 29, 1047-1057.	0.6	29
31	<scp>VEGF</scp> Pathways in the Lymphatics of Healthy and Diseased Heart. Microcirculation, 2016, 23, 5-14.	1.8	29
32	Donor Simvastatin Treatment in Heart Transplantation. Circulation, 2019, 140, 627-640.	1.6	24
33	Cancer risk and mortality after solid organ transplantation: A populationâ€based 30â€year cohort study in Finland. International Journal of Cancer, 2022, 150, 1779-1791.	5.1	24
34	VEGFR-1 and -2 Regulate Inflammation, Myocardial Angiogenesis, and Arteriosclerosis in Chronically Rejecting Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 819-825.	2.4	22
35	Vascular endothelial growth factor in chronic rat allograft nephropathy. Transplant Immunology, 2008, 19, 136-144.	1.2	21
36	Control of Early Aspergillus Mortality After Lung Transplantation: Outcome and Risk Factors. Transplantation Proceedings, 2010, 42, 4459-4464.	0.6	21

#	Article	IF	Citations
37	Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation, 2003, 75, 334-339.	1.0	20
38	Tacrolimus Treatment Effectively Inhibits Progression of Obliterative Airway Disease Even at Later Stages of Disease Development. Journal of Heart and Lung Transplantation, 2008, 27, 856-864.	0.6	19
39	Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts. American Journal of Transplantation, 2015, 15, 2075-2084.	4.7	19
40	Role of Endogenous Endothelin-1 in Transplant Obliterative Airway Disease in the Rat. American Journal of Transplantation, 2004, 4, 713-720.	4.7	18
41	Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion. Transplant Immunology, 2016, 37, 40-45.	1.2	17
42	Differential Effects of Pharmacological HIF Preconditioning of Donors Versus Recipients in Rat Cardiac Allografts. American Journal of Transplantation, 2013, 13, 600-610.	4.7	16
43	Immunobiology and pathology of chronic rejection. Transplantation Proceedings, 1997, 29, 77-78.	0.6	15
44	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in Deâ€novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. Clinical Transplantation, 2020, 34, e13984.	1.6	15
45	Induction of adhesion molecules on the endothelia of rejecting cardiac allografts. Journal of Heart and Lung Transplantation, 1995, 14, 205-13.	0.6	15
46	The Effect of Platelet-Derived Growth Factor Ligands in Rat Cardiac Allograft Vasculopathy and Fibrosis. Transplantation Proceedings, 2006, 38, 3271-3273.	0.6	14
47	Association between gastrointestinal symptoms and health-related quality of life after heart transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 1388-1394.	0.6	14
48	Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life. European Journal of Cardio-thoracic Surgery, 2019, 55, 780-787.	1.4	14
49	Cost-utility of venoarterial extracorporeal membrane oxygenation in cardiogenic shock and cardiac arrest. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 333-341.	1.0	14
50	CMV Infection and Allograft Rejection. Transplantation Proceedings, 1998, 30, 916-917.	0.6	13
51	Cardiomyocyte-targeted HIF-1Î± gene therapy inhibits cardiomyocyte apoptosis and cardiac allograft vasculopathy in the rat. Journal of Heart and Lung Transplantation, 2010, 29, 1058-1066.	0.6	13
52	Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts. Journal of Heart and Lung Transplantation, 2011, 30, 707-716.	0.6	13
53	Role of angiogenic growth factors in transplant coronary artery disease. Annals of Medicine, 2004, 36, 184-193.	3.8	12
54	Expression of platelet-derived growth factor in the development of cardiac allograft vasculopathy in the rat. Transplantation Proceedings, 1997, 29, 1045-1046.	0.6	11

#	Article	IF	Citations
55	Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. Journal of the American College of Cardiology, 2002, 39, 710-717.	2.8	11
56	Platelet-derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury. Transplantation, 2016, 100, 303-313.	1.0	11
57	Combined Donor Simvastatin and Methylprednisolone Treatment Prevents Ischemia-Reperfusion Injury in Rat Cardiac Allografts Through Vasculoprotection and Immunomodulation. Transplantation, 2013, 95, 1084-1091.	1.0	10
58	Cytomegalovirus infection enhances allograft arteriosclerosis in the rat. Transplantation Proceedings, 1993, 25, 1406-7.	0.6	10
59	Enhanced Intimal Proliferation upon Injury to Pre-Existing Neointima and Resistance of Neointimal Cells to Cell Death. Cardiovascular Pathology, 1999, 8, 339-347.	1.6	9
60	Donor simvastatin treatment and cardiac allograft ischemia/reperfusion injury. Trends in Cardiovascular Medicine, 2013, 23, 85-90.	4.9	9
61	Hypoxia-inducible factor controls immunoregulatory properties of myeloid cells in mouse cardiac allografts - an experimental study. Transplant International, 2019, 32, 95-106.	1.6	9
62	Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. Transplant International, 1994, 7, 363-364.	1.6	8
63	Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cmv infection in lung and heartâ€“lung allograft recipients. Transplantation Proceedings, 1999, 31, 163-164.	0.6	8
64	Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor. Transplantation Proceedings, 1999, 31, 187.	0.6	8
65	Cytomegalovirus infectionâ€”enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Transplantation Proceedings, 2001, 33, 1801.	0.6	8
66	Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts. Transplantation, 2004, 77, 655-658.	1.0	8
67	Effect of simvastatin on development of obliterative airway disease: An experimental study. Journal of Heart and Lung Transplantation, 2012, 31, 194-203.	0.6	8
68	Ex vivointracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. Transplant International, 2013, 26, 1126-1137.	1.6	8
69	Systemic overexpression of matricellular protein CCN1 exacerbates obliterative bronchiolitis in mouse tracheal allografts. Transplant International, 2015, 28, 1416-1425.	1.6	8
70	Vascular Endothelial Growth Factor Plays a Major Role in Development of Experimental Obliterative Bronchiolitis. Transplantation Proceedings, 2006, 38, 3266-3267.	0.6	7
71	Plasma proteome of brain-dead organ donors predicts heart transplant outcome. Journal of Heart and Lung Transplantation, 2022, 41, 311-324.	0.6	7
72	Cytomegalovirus infection accelerates mRNA expression of several smooth muscle cell growth factors in the allograft vascular wall. Transplantation Proceedings, 1995, 27, 566-7.	0.6	7

#	Article	IF	Citations
73	Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Transplantation Proceedings, 1999, 31, 102.	0.6	6
74	A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients. Transplant International, 2005, 18, 1318-1327.	1.6	6
75	Inhibition of Tumor Necrosis Factor-Î± Attenuates Myocardial Remodeling in Rat Cardiac Allografts. Journal of Heart and Lung Transplantation, 2006, 25, 569-578.	0.6	6
76	Inhibition of complement reduces obliterative bronchiolitis. Transplantation Proceedings, 1999, 31, 188.	0.6	5
77	PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Transplantation Proceedings, 2001, 33, 318.	0.6	5
78	Molecular mechanisms of chronic renal allograft rejection. Kidney International, Supplement, 1995, 52, S2-10.	0.1	5
79	Cytomegalovirus infection accelerates experimental obliterative bronchiolitis via platelet-derived growth factor upregulation. Transplantation Proceedings, 1997, 29, 798.	0.6	4
80	Triple-drug immunosuppression significantly reduces chronic rejection in noninfected and RCMV-infected rats. Transplantation Proceedings, 1994, 26, 1727-8.	0.6	4
81	Effect of Graft Preservation and Acute Rejection on Hypoxia-Inducible Factor-1 in Rat Cardiac Allografts. Transplantation Proceedings, 2006, 38, 3372-3373.	0.6	3
82	Angiogenic Growth Factors in Cardiac Allograft Rejection. Transplantation, 2006, 82, S22-S24.	1.0	3
83	Increased myeloid cell hypoxia-inducible factor-1 delays obliterative airway disease in the mouse. Journal of Heart and Lung Transplantation, 2016, 35, 671-678.	0.6	3
84	Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis. American Journal of Pathology, 2022, 192, 254-269.	3.8	3
85	Frequency of infections and their relation to episodes of acute rejection among heart allograft recipients. Presse Medicale, 1994, 23, 1252-6.	1.9	3
86	Failing Heart Transplants and Rejectionâ€"A Cellular Perspective. Journal of Cardiovascular Development and Disease, 2021, 8, 180.	1.6	3
87	Monogenic gene variants in lung transplant recipients with usual interstitial pneumonia. ERJ Open Research, 2022, 8, 00583-2021.	2.6	2
88	VEGF Receptor Signaling in the Cardiac Lymphatics. , 2013, , 125-143.		1
89	Simvastatin Treatment Upregulates Anti-Fibrotic Bone Morphogenetic Protein-7 Expression at Rat Cardiac Allograft Rejection. Pharmacology, 2016, 98, 204-208.	2.2	1
90	Cytomegalovirus infection accelerates obliterative bronchiolitis of rat tracheal allografts. , 1996, 9 Suppl 1, 221-222.		1

#	Article	IF	Citations
91	132. Journal of Heart and Lung Transplantation, 2006, 25, S89-S90.	0.6	0
92	334. Journal of Heart and Lung Transplantation, 2006, 25, S159.	0.6	0
93	335. Journal of Heart and Lung Transplantation, 2006, 25, S159.	0.6	0
94	232: Donor treatment with simvastatin abolishes ischemia-reperfusion injury in rat cardiac allografts. Journal of Heart and Lung Transplantation, 2007, 26, S143.	0.6	0
95	426: Vascular endothelial growth factor-C enhances experimental obliterative bronchiolitis by inducing lymphangiogenesis. Journal of Heart and Lung Transplantation, 2007, 26, S213-S214.	0.6	0
96	444: Persistent PDGF-A, -C, -D transgene expression enhances cardiac allograft vasculopathy and fibrosis, but PDGF-B induces myocardial angiogenesis. Journal of Heart and Lung Transplantation, 2007, 26, S220.	0.6	0
97	29: Role of Vascular Endothelial Growth Factor-C in Experimental Obliterative Airway Disease. Journal of Heart and Lung Transplantation, 2008, 27, S70.	0.6	0
98	232: Simvastatin Treatment Inhibits the Development of Obliterative Airway Disease in Rat Tracheal Allografts. Journal of Heart and Lung Transplantation, 2008, 27, S144.	0.6	0
99	310: Direct Microvascular Endothelial Stabilization by Donor Simvastatin Treatment Prevents Endothelial-to-Mesenchymal Transition and Vasculopathy of Cardiac Allografts. Journal of Heart and Lung Transplantation, 2010, 29, S105-S105.	0.6	0
100	418: Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Severe End Stage Pulmonary Disease. Journal of Heart and Lung Transplantation, 2010, 29, S138-S138.	0.6	0
101	354 Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease. Journal of Heart and Lung Transplantation, 2012, 31, S126.	0.6	0
102	498 Combined Prophylactic and Pre-Emptive CMV Strategy with Valganciclovir in Heart Transplant Patients Is Efficacious and Safe. Journal of Heart and Lung Transplantation, 2012, 31, S174-S175.	0.6	0
103	Ex Vivo Intracoronary Gene Transfer of Adeno Associated Virus Serotype 2 Is Superior to Serotypes 8 and 9 in Transfecting Heart Transplants in the Rat. Journal of Heart and Lung Transplantation, 2013, 32, S250-S251.	0.6	0
104	Transgenic Overexpression of Cardiac-Specific Vascular Endothelial Growth Factor B Exacerbates Ischemia Reperfusion Injury in Rat Cardiac Grafts.. Transplantation, 2014, 98, 352-353.	1.0	0
105	Donor Single-dose Treatment with VEGFR-3 Antibody Reduces Acute Alloimmune Response by Targeting Lymphatic Endothelial Cell Activation. Journal of Heart and Lung Transplantation, 2014, 33, S165.	0.6	0
106	Long-Term Outcomes of Left Ventricular Asisst Device Therapy in Scandinavia. Journal of Heart and Lung Transplantation, 2014, 33, S216.	0.6	0
107	Combined Short Term Caspofungin and Nebulized Amphotericin B Prophylaxis May Help To Eradicate Aspergillus Related Complications After Lung Transplantation. Journal of Heart and Lung Transplantation, 2014, 33, S180.	0.6	0
108	Cancer Risk After Heart Transplantation Highly Elevated in Comparison to General Population. Journal of Heart and Lung Transplantation, 2015, 34, S303-S304.	0.6	0

#	Article	IF	Citations
109	PDGF-B Is Protective During Ischemia-Reperfusion Injury in Rat Cardiac Allografts. Journal of Heart and Lung Transplantation, 2015, 34, S267-S268.	0.6	0
110	Lymphatic Endothelial Cell VEGFR3 Controls Cardiac Allograft Rejection. Journal of Heart and Lung Transplantation, 2015, 34, S93.	0.6	0
111	VEGF-B Overexpression Enhances Ischemia-Reperfusion Injury and the Innate Immune Response in Rat Heart Transplants. Journal of Heart and Lung Transplantation, 2015, 34, S264-S265.	0.6	0